Small Molecules

03 Apr 2017 Tetraphase Pharmaceuticals Completes Enrollment of IGNITE4 Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
03 Apr 2017 UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma
03 Apr 2017 eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017
03 Apr 2017 Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
03 Apr 2017 ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer's and Parkinson's diseases
03 Apr 2017 BioVie Receives FDA Clearance of IND Application for Phase 2a Clinical Trial in Refractory Ascites Patients
03 Apr 2017 Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia
03 Apr 2017 Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations
03 Apr 2017 Syros Presents New Preclinical Data at AACR Showing Anti-Tumor Activity of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Multiple Difficult-to-Treat Solid Tumors
03 Apr 2017 Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting
03 Apr 2017 Sierra Oncology Collaborator ICR Reports Preclinical Synthetic Lethality Data for Chk1 Inhibitor SRA737 at AACR
03 Apr 2017 ESSA Pharma Provides Clinical Study Update and Announces Presentations at the American Association for Cancer Research Annual Meeting
03 Apr 2017 Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer
03 Apr 2017 BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
03 Apr 2017 Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting
03 Apr 2017 Data on Verastem’s Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting
03 Apr 2017 Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting
03 Apr 2017 Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
03 Apr 2017 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
02 Apr 2017 Updated Phase 1 Data for IPI-549 Presented at AACR Annual Meeting 2017
01 Apr 2017 Intezyne Technologies Initiates First-In-Human Trials for Topoisomerase-1 Inhibitor IT-141; GRP78 Inhibitor IT-139 to be Featured in AACR Symposium
01 Apr 2017 Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting 2017
01 Apr 2017 IBRANCE® (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer
01 Apr 2017 Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation
01 Apr 2017 Tagrisso (osimertinib) receives US FDA full approval

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top